| scholarly article | Q13442814 |
| P50 | author | Shahab Asgharzadeh | Q55458999 |
| P2093 | author name string | Xiuhua Gao | |
| Nabil Ahmed | |||
| Jie Wei | |||
| Liping Song | |||
| Vita S Brawley | |||
| Daofeng Liu | |||
| Nathan Robison | |||
| Ashley Margol | |||
| Leonid S Metelitsa | |||
| Gengwen Tian | |||
| P2860 | cites work | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor | Q27681807 | ||
| Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 | ||
| Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. | Q33622444 | ||
| Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant | Q33628422 | ||
| Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment | Q33925291 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice | Q34564601 | ||
| Differential antitumor immunity mediated by NKT cell subsets in vivo | Q34603019 | ||
| The unconventional lifestyle of NKT cells | Q34770393 | ||
| Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals | Q35622939 | ||
| Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc | Q35818710 | ||
| A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma | Q36370927 | ||
| Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2 | Q36399484 | ||
| Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges | Q37388427 | ||
| The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis. | Q37884837 | ||
| Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile | Q38028930 | ||
| Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. | Q40070837 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma | Q40376124 | ||
| CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. | Q40451359 | ||
| Autologous natural killer cell therapy for human recurrent malignant glioma. | Q40531550 | ||
| Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells | Q40781889 | ||
| Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells | Q44452165 | ||
| Regression of experimental medulloblastoma following transfer of HER2-specific T cells | Q45868854 | ||
| Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans | Q46718817 | ||
| Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion | Q47935150 | ||
| Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development | Q48347333 | ||
| Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. | Q48439090 | ||
| Loss of IFN-gamma production by invariant NK T cells in advanced cancer. | Q52934636 | ||
| Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 | ||
| c-Myc promoter activation in medulloblastoma. | Q55472620 | ||
| Antigen-specific regulation of CD1 expression in humans | Q74169467 | ||
| Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide | Q74261475 | ||
| P433 | issue | 1 | |
| P921 | main subject | medulloblastoma | Q1333608 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 55-64 | |
| P577 | publication date | 2013-06-18 | |
| P1433 | published in | Clinical Immunology | Q15752921 |
| P1476 | title | Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells | |
| P478 | volume | 149 |
| Q64969808 | Adoptive Cell Therapy in Treating Pediatric Solid Tumors. |
| Q26998503 | Adoptive T Cell Therapy Targeting CD1 and MR1 |
| Q92481897 | CAR-armed cell therapy for gliomas |
| Q64091306 | CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity |
| Q36951719 | CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo |
| Q27014912 | Cellular immunotherapy for pediatric solid tumors |
| Q45871070 | Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. |
| Q52715479 | Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. |
| Q94527860 | Immunotherapy for Medulloblastoma: Current Perspectives |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q34389948 | Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes |
| Q38376606 | Medulloblastoma development: tumor biology informs treatment decisions |
| Q36026142 | Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors |
| Q64900090 | NKT Cells in Neurological Diseases. |
| Q42078314 | Natural Killer T Cells in Cancer Immunotherapy |
| Q52645931 | Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy. |
| Q35952443 | Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors |
| Q52733768 | Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. |
| Q38616499 | Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). |
| Q55094012 | The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach. |
| Q27023425 | The regulatory role of invariant NKT cells in tumor immunity |
| Q48608874 | Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. |
| Q40135347 | Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. |
| Q99711511 | Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells |
Search more.